Hide metadata

dc.date.accessioned2015-02-24T08:18:15Z
dc.date.available2015-02-24T08:18:15Z
dc.date.created2014-08-29T10:28:04Z
dc.date.issued2014
dc.identifier.citationHiorth, Marianne Nilsen, Susanne Tho, Ingunn . Bioadhesive Mini-Tablets for Vaginal Drug Delivery. Pharmaceutics. 2014, 6(3), 494-511
dc.identifier.urihttp://hdl.handle.net/10852/42556
dc.description.abstractDifferent non-ionic cellulose ethers (methyl cellulose, MC; hydroxyethyl cellulose, HEC; hydroxypropyl cellulose, HPC; hydroxypropylmethyl cellulose, HPMC) and microcrystalline cellulose (MCC) were investigated as matrix formers for preparation of mini-tablets targeting vaginal drug delivery. Hexyl aminolevulinat hydrochloridum (HAL) was used as a model drug. The mini-tablets were characterized with respect to their mechanical strength, bioadhesion towards cow vaginal tissue in two independent tests (rotating cylinder test, detachment test using texture analyzer), and dissolution rate in two media mimicking the pH levels of fertile, healthy and post-menopausal women (vaginal fluid simulant pH 4.5, phosphate buffer pH 6.8). Mini-tablets with a matrix of either HPMC or HPC were found to possess adequate mechanical strength, superior bioadhesive behavior towards vaginal tissue, and pH independent controlled release of the model drug, suggesting that both systems would be suited for the treatment of women regardless of age, i.e., respective of their vaginal pH levels. Bioadhesive mini-tablets offer a potential for improved residence time in the vaginal cavity targeting contact with mucosal tissue and prolonged release of the drug.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherMDPI AG
dc.rightsAttribution 3.0 Unported
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.titleBioadhesive Mini-Tablets for Vaginal Drug Deliveryen_US
dc.typeJournal articleen_US
dc.creator.authorHiorth, Marianne
dc.creator.authorNilsen, Susanne
dc.creator.authorTho, Ingunn
cristin.unitcode185,15,23,10
cristin.unitnameFarmasi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1150297
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.volume=6&rft.spage=494&rft.date=2014
dc.identifier.jtitlePharmaceutics
dc.identifier.volume6
dc.identifier.issue3
dc.identifier.startpage494
dc.identifier.endpage511
dc.identifier.doihttp://dx.doi.org/10.3390/pharmaceutics6030494
dc.identifier.urnURN:NBN:no-46944
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1999-4923
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/42556/1/Hiorth_Pharmacuetics_2014.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 3.0 Unported
This item's license is: Attribution 3.0 Unported